
Events/N
GV
Capecitabine
HR (95% CI)
Median (months)
GV
Capecitabine
P Value
Overall 134 / 218 65 / 109 1.06 [0.78, 1.43] 8.9 8.7 0.7255
Age
<=40 23 / 31 12 / 15 1.95 [0.86, 4.43] 5.5 8.6 0.1037
41 - 64 87 / 146 36 / 66 0.85 [0.57, 1.27] 9.0 8.2 0.4255
>=65 24 / 41 17 / 28 1.53 [0.76, 3.07] 10.7 10.8 0.2270
Race
White 111 / 176 51 / 91 1.12 [0.80, 1.58] 8.8 9.0 0.5095
Other 15 / 26 11 / 11 0.76 [0.29, 2.02] 9.9 8.2 0.5809
Unknown 8 / 16 3 / 7 1.07 [0.23, 4.98] 6.5 10.8 0.9325
Region
North America 100 / 148 53 / 79 1.00 [0.71, 1.42] 8.8 8.0 0.9958
Other 34 / 70 12 / 30 1.60 [0.75, 3.40] 10.6 11.7 0.2218
Prior Lines Adv. Dis.
0-1 102 / 168 48 / 85 1.11 [0.78, 1.58] 9.8 9.5 0.5650
2 32 / 50 17 / 24 0.91 [0.50, 1.67] 7.1 6.7 0.7614
Prog Free Intrvl Taxane
<=6 months 74 / 112 32 / 51 1.24 [0.80, 1.91] 6.9 8.3 0.3345
>6 months 60 / 106 33 / 58 0.90 [0.58, 1.38] 10.3 9.2 0.6173
Prior Anthracycline
Yes 121 / 185 58 / 95 1.15 [0.84, 1.59] 8.4 8.7 0.3839
No 13 / 33 7 / 14 0.41 [0.15, 1.08] 16.8 8.0 0.0628
0.1
1
10
<-----Favors GV
Favors Capecitabine->


Events/N
GV
Capecitabine
HR (95% CI)
Median (months)
GV
Capecitabine
P Value
CNS Involvement
Yes 15 / 20 4 / 6 1.56 [0.21, 11.70] 5.5 5.7 0.6622
No 119 / 198 61 / 103 1.03 [0.74, 1.42] 9.4 8.7 0.8713
GPNMB Expression
25-<50% 49 / 78 25 / 43 1.16 [0.69, 1.95] 8.6 8.1 0.5748
>=50% 85 / 140 39 / 65 1.25 [0.83, 1.87] 9.0 8.3 0.2816
ER/PR Status
Both <1% 116 / 189 60 / 98 1.06 [0.77, 1.46] 8.8 8.7 0.7332
Both <10%, either 1-9% 17 / 28 5 / 11 1.36 [0.37, 5.06] 10.3 6.7 0.6452
ECOG PS
0 59 / 106 33 / 60 1.08 [0.68, 1.69] 10.5 10.6 0.7485
1 74 / 111 32 / 47 1.04 [0.67, 1.62] 7.3 7.1 0.8609
2 1 / 1 0 / 1 4.2 -
Visceral Disease
Yes 115 / 173 50 / 80 1.01 [0.72, 1.43] 8.4 8.0 0.9354
No 19 / 45 15 / 29 0.84 [0.39, 1.80] 14.3 11.7 0.6568
Disease Sites
1 15 / 33 14 / 32 1.09 [0.49, 2.41] 13.4 18.6 0.8307
2 35 / 73 14 / 26 0.97 [0.50, 1.88] 11.1 9.5 0.9223
>=3 84 / 112 37 / 51 0.93 [0.62, 1.39] 7.0 6.8 0.7179
0.1
1
10
<-----Favors GV
Favors Capecitabine->

Supplementary Figure 1. Overall Survival by Subgroup Analysis

Overall survival was determined in the Intention-to-Treat Population. Subgroup analysis was performed by demographics and by study prespecified randomization factors: number of prior lines of cytotoxic chemotherapy for advanced disease, progression-free interval post last receipt of taxane, and prior receipt of anthracycline.

A


Number or Prior Taxane Therapies: 0-1
Progression Free Survival
1.0
0.8
0.6
0.4
0.2
0.0
0
2
4
6
8
10
12
14
16
18
20
Months
1: Glembatumumab Vedotin
2: Capecitabine
Events / N Median (95% CI)
Glembatumumab Vedotin 116 / 164 3.0 (2.8, 3.9)
Capecitabine 48 / 75 1.9 (1.5, 3.1)
HR (95% CI): 0.67 (0.47, 0.95)
P: 0.0223
Subjects At Risk
1 164 96 52 21 8 2 1 1 0
2 75 25 13 3 2 1 0

B


Number or Prior Taxane Therapies: >=2
Progression Free Survival
1.0
0.8
0.6
0.4
0.2
0.0
Events / N Median (95% CI)
Glembatumumab Vedotin 38 / 54 2.7 (1.8, 3.0)
Capecitabine 21 / 34 3.2 (1.9, 6.9)
HR (95% CI): 1.70 (0.94, 3.07)
P: 0.0782
1: Glembatumumab Vedotin
2: Capecitabine
0 2 4 6 8 10 12 14 16 18 20
Months
Subjects At Risk
1 54 29 13 4 1 1 0
2 34 18 12 7 6 3 2 2 1 0

C


Number or Prior Taxane Therapies: 0-1
Events / N Median (95% CI)
Glembatumumab Vedotin 100 / 164 9.4 (8.4, 10.7)
Capecitabine 45 / 75 9.5 (6.7, 11.3)
HR (95% CI): 0.96 (0.67, 1.38)
P: 0.8435
Overall Survival
1.0
0.8
0.6
0.4
0.2
0.0
1: Glembatumumab Vedotin
2: Capecitabine
0 2 4 6 8 10 12 14 16 18 20 22 24 26 28 30 32 34 36 38 40
Months
Subjects At Risk
1 164 153 129 92 72 53 35 27 25 19 17 11 8 4 3 3 2 1 0
2 75 65 50 43 34 22 15 10 10 10 7 7 7 6 4 3 2 1 1 0

D


Number or Prior Taxane Therapies: >=2
Overall Survival
1.0
0.8
0.6
0.4
0.2
0.0
Events / N Median (95% CI)
Glembatumumab Vedotin 34 / 54 7.9 (6.4, 11.7)
Capecitabine 20 / 34 10.6 (7.1, 21.9)
HR (95% CI): 1.48 (0.83, 2.65)
P: 0.1817
1: Glembatumumab Vedotin
2: Capecitabine
0 2 4 6 8 10 12 14 16 18 20 22 24 26 28 30 32 34 36 38 40
Months
Subjects At Risk
1 54 50 43 29 19 13 10 9 4 4 4 4 4 3 2 1 0
2 34 31 29 23 16 13 12 12 11 8 5 3 2 1 0

Supplementary Figure 2. Kaplan-Meier Estimates of Progression-Free and Overall Survival by Prior Lines of Taxane

Exploratory post-hoc analysis of progression-free survival and overall survival. PFS by IRC assessment by subgroups (A) 0-1 prior line of a taxane-containing regimen and (B) two prior lines of a taxane-containing regimen. OS by subgroups (C) 0-1 prior line of a taxane-containing regimen and (D) two prior lines of a taxane-containing regimen. Tick marks represent censored data.

Supplementary Table 1. Additional Anticancer Medications Received in the Post-Treatment Follow-Up Period

	Glembatumumab vedotin	Capecitabine	Overall
ITT Population	N=218	N=109	N=327
Capecitabine	29%	3%	20%
Eribulin[1]	18%	25%	21%
Gemcitabine[2]	14%	10%	13%
Carboplatin	13%	13%	13%
Doxorubicin[3]	9%	8%	9%
Paclitaxel[4]	7%	3%	5%
Cyclophosphamide	4%	5%	4%
Pembrolizumab	4%	4%	4%
Vinorelbine[5]	4%	5%	4%
Investigational	3%	3%	3%
Bevacizumab	3%	1%	2%
Docetaxel	2%	1%	2%
Ixabepilone	1%	4%	2%
Olaparib	1%	4%	2%
Everolimus	1%	2%	1%
Fluorouracil	1%	2%	1%
Methotrexate	1%	2%	1%
Cisplatin	1%	1%	1%
Epirubicin	1%	1%	1%
Irinotecan	1%	1%	1%
Monoclonal antibodies (investigational)	1%	1%	1%
Nivolumab	1%	1%	1%
Pertuzumab	1%	1%	1%
Pexidartinib	1%	1%	1%
Sacituzumab govitecan	1%	1%	1%
Trastuzumab	1%	1%	1%
Etoposide	1%	0%	<1%
Pemetrexed	1%	0%	<1%
Seviteronel	1%	0%	<1%
Ibrutinib	0%	1%	<1%
Mitomycin	0%	1%	<1%

1. Includes eribulin mesylate
2. Includes gemcitabine hydrochloride
3. Includes doxorubicin hydrochloride and pegylated liposomal doxorubicin hydrochloride
4. Includes paclitaxel albumin
5. Includes vinorelbine tartrate

Supplementary Table 2. Antitumor Activity by Investigator Review

	Glembatumumab vedotin		Capecitabine	
ITT Population	N=218		N=109	
PFS				
Median, months (95% CI)	2.9	(2.8, 3.1)	2.7	(1.8, 3.4)
Measurable Disease ITT Population	N=214		N=108	
ORR, n (% [95% CI])	63 (29%)	23.4, 36.0	23 (21%)	14.0, 30.2
Confirmed CR, n (%)	5 (2%)		4 (4%)	
Confirmed PR, n (%)	58 (27%)		19 (18%)	
Any Response*, n (% [95% CI])	63 (29%)	23.4, 36.0	23 (21%)	14.0, 30.2
SD, n (%)	73 (34%)		28 (26%)	

Abbreviations: ITT, Intention-to-Treat population, includes all enrolled patients; PFS, Progression-Free Survival; ORR, Objective Response Rate per RECIST 1.1; CR, Complete Response; PR, Partial Response; SD, Stable Disease (minimum interval ≥ 6 weeks from baseline); DOR, Duration of Response.

*Any response including those not confirmed at subsequent disease assessment